Esra Balıkçı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Esra Balıkçı has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Kilian V. M. Huber
Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3 shared publications - Caner Akıl
Chinese Academy of Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2 shared publications - Cornelia Kilchert
Institut für Biochemie, Justus-Liebig-Universität Gießen, Gießen, Germany
2 shared publications - Jonathan M. Grimes
Division of Structural Biology, Centre for Human Genetics, University of Oxford, Oxford, UK
2 shared publications - Krzysztof Kus
University of Oxford
2 shared publications - Lidia Vasiljeva
Department of Biochemistry, University of Oxford, Oxford, UK
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Unveiling structural determinants of peptide recognition by public and private SARS-CoV-2-specific T-cell receptors
Public T cell receptors (TCRs) recurrently emerge across individuals in response to common pathogens, yet the structural and biophysical basis distinguishing public from private clonotypes remains incompletely defined. Here, we combine epitope mapping, single-cell TCR sequencing, and single-particle cryo-electron microscopy to dissect CD8 + T cell responses to the immunodominant SARS-CoV-2 ORF3a (207-215) epitope presented by HLA-A*01:01. Among responding clonotypes, we identify a public TCR (TCR pub ), shared across donors, and a private TCR (TCR priv ) that uses nearly identical β chains but distinct α chains. Despite comparable micromolar affinities and functional avidities, cryo-EM structures at ~3 Å resolution reveal that the two receptors engage the peptide-MHC complex through distinct CDR-loop configurations and contact footprints. TCR pub establishes contacts with the peptide and the MHC α2-helix primarily through the CDR2β and CDR3β loops, whereas TCR priv distributes contacts across both MHC α-helices and engages the peptide via multiple CDR loops. In agreement with these observations, alanine-scanning mutagenesis reveals that TCR pub shows greater sensitivity to peptide substitutions, consistent with its peptide-focused binding mode. These findings demonstrate how alternative α-chain pairing reconfigures the antigen-binding interface within a shared β-chain.
- 22 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessUnveiling structural determinants of peptide recognition by public and private SARS-CoV-2-specific T-cell receptors
Public T cell receptors (TCRs) recurrently emerge across individuals in response to common pathogens, yet the structural and biophysical basis distinguishing public from private clonotypes remains incompletely defined. Here, we combine epitope mapping, single-cell TCR sequencing, and single-particle cryo-electron microscopy to dissect CD8 + T cell responses to the immunodominant SARS-CoV-2 ORF3a (207-215) epitope presented by HLA-A*01:01. Among responding clonotypes, we identify a public TCR (TCR pub ), shared across donors, and a private TCR (TCR priv ) that uses nearly identical β chains but distinct α chains. Despite comparable micromolar affinities and functional avidities, cryo-EM structures at ~3 Å resolution reveal that the two receptors engage the peptide-MHC complex through distinct CDR-loop configurations and contact footprints. TCR pub establishes contacts with the peptide and the MHC α2-helix primarily through the CDR2β and CDR3β loops, whereas TCR priv distributes contacts across both MHC α-helices and engages the peptide via multiple CDR loops. In agreement with these observations, alanine-scanning mutagenesis reveals that TCR pub shows greater sensitivity to peptide substitutions, consistent with its peptide-focused binding mode. These findings demonstrate how alternative α-chain pairing reconfigures the antigen-binding interface within a shared β-chain.
- Open Access
- 15 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
WDR82 code coordinates transcription and pre-mRNA 3′-end processing through regulated phosphorylation
Phosphorylation plays a central role in coordinating transcription with pre-mRNA maturation, yet the mechanistic understanding of how transcription is regulated by phosphorylation remains limited. The PP1 phosphatase removes Cdk9-dependent phosphorylation of Pol II and Spt5, triggering transcription termination. Here, we demonstrate that PNUTS enhances PP1 activity, whereas WDR82 mediates an interaction between PP1 and the pre-mRNA 3′-end processing machinery subunit Symplekin. We present the structure of a PNUTS-WDR82-Symplekin-Ssu72 complex, revealing that PNUTS and Symplekin bind WDR82 through distinct interfaces using conserved short linear motifs. Mutations that inactivate PP1’s catalytic activity or disrupt its interaction with either PNUTS or the 3′-end processing machinery led to impaired transcription elongation, inefficient cleavage of nascent transcripts, altered poly(A) site selection, and widespread transcription termination defects. Our findings demonstrate that the PP1 complex is essential for coupling transcription to pre-mRNA 3′-end maturation, ensuring production of functional mRNA.
- 15 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessWDR82 code coordinates transcription and pre-mRNA 3′-end processing through regulated phosphorylation
Phosphorylation plays a central role in coordinating transcription with pre-mRNA maturation, yet the mechanistic understanding of how transcription is regulated by phosphorylation remains limited. The PP1 phosphatase removes Cdk9-dependent phosphorylation of Pol II and Spt5, triggering transcription termination. Here, we demonstrate that PNUTS enhances PP1 activity, whereas WDR82 mediates an interaction between PP1 and the pre-mRNA 3′-end processing machinery subunit Symplekin. We present the structure of a PNUTS-WDR82-Symplekin-Ssu72 complex, revealing that PNUTS and Symplekin bind WDR82 through distinct interfaces using conserved short linear motifs. Mutations that inactivate PP1’s catalytic activity or disrupt its interaction with either PNUTS or the 3′-end processing machinery led to impaired transcription elongation, inefficient cleavage of nascent transcripts, altered poly(A) site selection, and widespread transcription termination defects. Our findings demonstrate that the PP1 complex is essential for coupling transcription to pre-mRNA 3′-end maturation, ensuring production of functional mRNA.
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Targeted Protein Degradation of NUDT5 Dissociates Catalytic Inhibition from Protein Loss in 6-Thioguanine Response
6-Thioguanine (6-TG) is an FDA-approved antimetabolite drug that is widely used clinically, including for the treatment of leukemia. Its cellular effects require metabolic activation and are regulated through interactions with various proteins such as NUDT15, which catalyzes the hydrolysis of the active 6-TG metabolites 6-thio-deoxyGTP (6-thio-dGTP) and 6-thio-GTP. Recent genome-wide CRISPR loss-of-function studies have identified another NUDIX hydrolase, NUDT5, as a crucial mediator of 6-TG toxicity. Here, we develop and validate a selective, cell-active NUDT5 degrader toolkit and orthogonally characterize target engagement, ternary complex formation, degradation kinetics, and proteome-wide selectivity. These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG. Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition, suggesting a distinct mode-of-action with potential implications for patient therapy.
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTargeted Protein Degradation of NUDT5 Dissociates Catalytic Inhibition from Protein Loss in 6-Thioguanine Response
6-Thioguanine (6-TG) is an FDA-approved antimetabolite drug that is widely used clinically, including for the treatment of leukemia. Its cellular effects require metabolic activation and are regulated through interactions with various proteins such as NUDT15, which catalyzes the hydrolysis of the active 6-TG metabolites 6-thio-deoxyGTP (6-thio-dGTP) and 6-thio-GTP. Recent genome-wide CRISPR loss-of-function studies have identified another NUDIX hydrolase, NUDT5, as a crucial mediator of 6-TG toxicity. Here, we develop and validate a selective, cell-active NUDT5 degrader toolkit and orthogonally characterize target engagement, ternary complex formation, degradation kinetics, and proteome-wide selectivity. These degraders, in conjunction with orthogonal CRISPR knock-out and reconstitution experiments, support a non-enzymatic role for NUDT5 in modulating the cellular response to 6-TG. Depletion of NUDT5 protein is antagonistic to NUDT15 inhibition, suggesting a distinct mode-of-action with potential implications for patient therapy.
- Open Access
Biophysical Sensing Tools in Drug Discovery: Integrating Kinetics, Thermodynamics, Cellular Target Engagement and Structure
Biophysical sensing technologies have become central to modern drug discovery because they enable direct, quantitative characterization of ligand–target interactions. In contrast to conventional biochemical and cellular assays that infer binding from downstream functional responses, biophysical methods detect interaction events through measurable physical changes such as refractive index, heat, fluorescence, mass, or protein stability. This review surveys the major classes of biophysical sensors used in drug discovery, including surface-based optical methods, calorimetry, solution-state spectroscopic techniques, mass spectrometry-based approaches, and cellular target engagement assays. For each modality, we outline the measurement principle, the key parameters obtained, and its value across hit identification, hit validation, lead optimization, and mechanism-of-action studies. We also emphasize the growing importance of combining orthogonal methods to improve confidence in binding data, resolve assay artifacts, and strengthen early decision-making. Finally, we discuss how biophysical measurements are increasingly integrated with structural biology and computational analysis to support more predictive and mechanism-driven discovery workflows. Collectively, these technologies provide a richer and more reliable understanding of molecular recognition and thereby improve the progression of drug candidates.
Open AccessBiophysical Sensing Tools in Drug Discovery: Integrating Kinetics, Thermodynamics, Cellular Target Engagement and Structure
Biophysical sensing technologies have become central to modern drug discovery because they enable direct, quantitative characterization of ligand–target interactions. In contrast to conventional biochemical and cellular assays that infer binding from downstream functional responses, biophysical methods detect interaction events through measurable physical changes such as refractive index, heat, fluorescence, mass, or protein stability. This review surveys the major classes of biophysical sensors used in drug discovery, including surface-based optical methods, calorimetry, solution-state spectroscopic techniques, mass spectrometry-based approaches, and cellular target engagement assays. For each modality, we outline the measurement principle, the key parameters obtained, and its value across hit identification, hit validation, lead optimization, and mechanism-of-action studies. We also emphasize the growing importance of combining orthogonal methods to improve confidence in binding data, resolve assay artifacts, and strengthen early decision-making. Finally, we discuss how biophysical measurements are increasingly integrated with structural biology and computational analysis to support more predictive and mechanism-driven discovery workflows. Collectively, these technologies provide a richer and more reliable understanding of molecular recognition and thereby improve the progression of drug candidates.
- Open Access
The PP1 phosphatase complex coordinates pre-mRNA 3׳end processing and termination of RNA polymerase II transcription
Phosphorylation plays a central role in coordinating transcription with pre-mRNA maturation, yet the mechanistic understanding of how transcription is regulated by phosphorylation remains limited. The PP1 phosphatase removes CDK9 dependent phosphorylation of Pol II and Spt5, triggering transcription termination. Here, we demonstrate that PNUTS enhances PP1 activity, whereas WDR82 mediates an interaction between PP1 and the pre-mRNA 3׳ end processing machinery subunit Symplekin. We present the first structure of a PNUTS-WDR82-Symplekin-Ssu72 complex, revealing that PNUTS and Symplekin bind WDR82 through distinct interfaces using conserved short linear motifs. Mutations that inactivate PP1's catalytic activity or disrupt its interaction with either PNUTS or the 3׳end processing machinery led to impaired transcription elongation, inefficient cleavage of nascent transcripts, altered poly(A) site selection, and widespread transcription termination defects. Our findings demonstrate that the PP1 complex is essential for coupling transcription to pre-mRNA 3׳end maturation, ensuring production of functional mRNA.
Open AccessThe PP1 phosphatase complex coordinates pre-mRNA 3׳end processing and termination of RNA polymerase II transcription
Phosphorylation plays a central role in coordinating transcription with pre-mRNA maturation, yet the mechanistic understanding of how transcription is regulated by phosphorylation remains limited. The PP1 phosphatase removes CDK9 dependent phosphorylation of Pol II and Spt5, triggering transcription termination. Here, we demonstrate that PNUTS enhances PP1 activity, whereas WDR82 mediates an interaction between PP1 and the pre-mRNA 3׳ end processing machinery subunit Symplekin. We present the first structure of a PNUTS-WDR82-Symplekin-Ssu72 complex, revealing that PNUTS and Symplekin bind WDR82 through distinct interfaces using conserved short linear motifs. Mutations that inactivate PP1's catalytic activity or disrupt its interaction with either PNUTS or the 3׳end processing machinery led to impaired transcription elongation, inefficient cleavage of nascent transcripts, altered poly(A) site selection, and widespread transcription termination defects. Our findings demonstrate that the PP1 complex is essential for coupling transcription to pre-mRNA 3׳end maturation, ensuring production of functional mRNA.
- Open Access
- 3 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10129
A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells
Protein arginine methyl transferase 5 (PRMT5) plays a global role in cell physiology and is an established therapeutic target in cancer. In approximately 10-15% of human cancers, deletion of the methylthioadenosine phosphorylase (MTAP) gene results in accumulation of methylthioadenosine (MTA), exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate S-adenosyl methionine (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Although uncompetitive engagement can be evaluated in cell-free systems, no methods exist to directly assess this in cells. Here, we describe the development of a fluorescent probe that acts as a dynamic BRET biosensor of the intracellular SAM/MTA pool that overcomes the current limitations of competitive binding analyses. Using this biosensor, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement as well as ternary complex formation at PRMT5-SAM and PRMT5-MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent responses of inhibitors.
- 3 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10129
Open AccessA BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells
Protein arginine methyl transferase 5 (PRMT5) plays a global role in cell physiology and is an established therapeutic target in cancer. In approximately 10-15% of human cancers, deletion of the methylthioadenosine phosphorylase (MTAP) gene results in accumulation of methylthioadenosine (MTA), exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate S-adenosyl methionine (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Although uncompetitive engagement can be evaluated in cell-free systems, no methods exist to directly assess this in cells. Here, we describe the development of a fluorescent probe that acts as a dynamic BRET biosensor of the intracellular SAM/MTA pool that overcomes the current limitations of competitive binding analyses. Using this biosensor, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement as well as ternary complex formation at PRMT5-SAM and PRMT5-MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent responses of inhibitors.
- Open Access
- 6 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A Live Cell BRET Probe to Quantify PRMT5-MTA Uncompetitive Target Engagement
The PRMT5 methyltransferase plays a global role in cell physiology and is an established therapeutic target in cancer. In 10% of human cancers, deletion of the MTAP gene results in accumulation of MTA, exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Here we describe the development of a cell-permeable BRET probe CBH-002 that acts as a dynamic biosensor of the intracellular SAM/MTA pool. Using this probe, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement and ternary complex formation at PRMT5-SAM and -MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent response to inhibitors.
- 6 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Live Cell BRET Probe to Quantify PRMT5-MTA Uncompetitive Target Engagement
The PRMT5 methyltransferase plays a global role in cell physiology and is an established therapeutic target in cancer. In 10% of human cancers, deletion of the MTAP gene results in accumulation of MTA, exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Here we describe the development of a cell-permeable BRET probe CBH-002 that acts as a dynamic biosensor of the intracellular SAM/MTA pool. Using this probe, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement and ternary complex formation at PRMT5-SAM and -MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent response to inhibitors.
- Open Access
- 30 December 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (2) , 563-586
Structure of the Nipah virus polymerase complex
Nipah virus is a highly virulent zoonotic paramyxovirus causing severe respiratory and neurological disease. Despite its lethality, there is no approved treatment for Nipah virus infection. The viral polymerase complex, composed of the polymerase (L) and phosphoprotein (P), replicates and transcribes the viral RNA genome. Here, we describe structures of the Nipah virus L-P polymerase complex and the L-protein’s Connecting Domain (CD). The cryo-electron microscopy L-P complex structure reveals the organization of the RNA-dependent RNA polymerase (RdRp) and polyribonucleotidyl transferase (PRNTase) domains of the L-protein, and shows how the P-protein, which forms a tetramer, interacts with the RdRp-domain of the L-protein. The crystal structure of the CD-domain alone reveals binding of three Mg ions. Modelling of this domain onto an AlphaFold 3 model of an RNA-L-P complex suggests a catalytic role for one Mg ion in mRNA capping. These findings offer insights into the structural details of the L-P polymerase complex and the molecular interactions between L-protein and P-protein, shedding light on the mechanisms of the replication machinery. This work will underpin efforts to develop antiviral drugs that target the polymerase complex of Nipah virus.
- 30 December 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (2) , 563-586
Open AccessStructure of the Nipah virus polymerase complex
Nipah virus is a highly virulent zoonotic paramyxovirus causing severe respiratory and neurological disease. Despite its lethality, there is no approved treatment for Nipah virus infection. The viral polymerase complex, composed of the polymerase (L) and phosphoprotein (P), replicates and transcribes the viral RNA genome. Here, we describe structures of the Nipah virus L-P polymerase complex and the L-protein’s Connecting Domain (CD). The cryo-electron microscopy L-P complex structure reveals the organization of the RNA-dependent RNA polymerase (RdRp) and polyribonucleotidyl transferase (PRNTase) domains of the L-protein, and shows how the P-protein, which forms a tetramer, interacts with the RdRp-domain of the L-protein. The crystal structure of the CD-domain alone reveals binding of three Mg ions. Modelling of this domain onto an AlphaFold 3 model of an RNA-L-P complex suggests a catalytic role for one Mg ion in mRNA capping. These findings offer insights into the structural details of the L-P polymerase complex and the molecular interactions between L-protein and P-protein, shedding light on the mechanisms of the replication machinery. This work will underpin efforts to develop antiviral drugs that target the polymerase complex of Nipah virus.